Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9243041-B2
Application number	US-201213982457-A
Country	US
Kind code	B2
Filing date	Jan 31, 2012
Priority date	Jan 31, 2011
Publication date	Jan 26, 2016
Grant date	Jan 26, 2016

Abstract

Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of herpes virus antigens, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against herpes virus using the vaccines that are provided.

First claim

The invention claimed is:

1. A nucleic acid molecule comprising a coding sequence for a human cytomegalovirus (HCMV) antigen encoding one or more proteins selected from the group consisting of:
a protein that is at least 95% identical to SEQ ID NO:2 or comprises SEQ ID NO:2;
a protein that is at least 95% identical to SEQ ID NO:4 or comprises SEQ ID NO:4;
a protein that is at least 95% identical to SEQ ID NO:6 or comprises SEQ ID NO:6;
a protein that comprises SEQ ID NO:8;
a protein that is at least 95% identical to SEQ ID NO:10 or comprises SEQ ID NO:10;
a protein that is at least 95% identical to SEQ ID NO:12 or comprises SEQ ID NO:12;
a protein that is at least 97% identical to SEQ ID NO:14 or comprises SEQ ID NO:14;
a protein that is at least 97% identical to SEQ ID NO:16 or comprises SEQ ID NO:16;
a protein that is at least 95% identical to SEQ ID NO:18 or comprises SEQ ID NO:18; and
a protein that is at least 98% identical to SEQ ID NO:20 or comprises SEQ ID NO:20.

2. The nucleic acid molecule of claim 1 , encoding one or more proteins selected from the group consisting of: SEQ ID NO:2; SEQ ID NO:4; SEQ ID NO:6; SEQ ID NO:8; SEQ ID NO:10; SEQ ID NO:12; SEQ ID NO:14, SEQ ID NO:16; SEQ ID NO:18, and SEQ ID NO:20.

3. The nucleic acid molecule of claim 1 , comprising one or more sequences selected from the group consisting of:
a nucleic acid sequence that is at least 95% identical to SEQ ID NO:1 or comprises SEQ ID NO:1;
a nucleic acid sequence that is at least 95% identical to SEQ ID NO:3 or comprises SEQ ID NO:3;
a nucleic acid sequence that is at least 95% identical to SEQ ID NO:5 or comprises SEQ ID NO:5;
a nucleic acid sequence that comprises SEQ ID NO:7;
a nucleic acid sequence that is at least 95% identical to SEQ ID NO:9 or comprises SEQ ID NO:9;
a nucleic acid sequence that is at least 95% identical to SEQ ID NO:11 or comprises SEQ ID NO:11;
a nucleic acid sequence that is at least 97% identical to SEQ ID NO:13 or comprises SEQ ID NO:13;
a nucleic acid sequence that is at least 97% identical to SEQ ID NO:15 or comprises SEQ ID NO:15;
a nucleic acid sequence that is at least 95% identical to SEQ ID NO:17 or comprises SEQ ID NO:17; and
a nucleic acid sequence that is at least 98% identical to SEQ ID NO:19 or comprises SEQ ID NO:19.

4. The nucleic acid molecule of claim 1 , comprising one or more nucleotide sequences selected from the group consisting of: SEQ ID NO:1; SEQ ID NO:3; SEQ ID NO:5; SEQ ID NO:7; SEQ ID NO:9; SEQ ID NO:11; SEQ ID NO:13; SEQ ID NO:15; SEQ ID NO:17; SEQ ID NO:19; SEQ ID NO:21; SEQ ID NO:23; SEQ ID NO:25; SEQ ID NO:27; SEQ ID NO:29; SEQ ID NO:31; SEQ ID NO:33; SEQ ID NO:35; SEQ ID NO:37; SEQ ID NO:39, SEQ ID NO:41; SEQ ID NO:43; SEQ ID NO:45; SEQ ID NO:47; SEQ ID NO:49; SEQ ID NO:51; SEQ ID NO:53; SEQ ID NO:55; SEQ ID NO:57; and SEQ ID NO:59.

5. The nucleic acid molecule of claim 4 , wherein the nucleic acid molecule is a DNA plasmid.

6. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule further comprises a second nucleic acid sequence that is heterologous to the first nucleic acid sequence, wherein the second nucleic acid sequence encodes a protein selected from the group consisting of: HCMV gB, HCMV gM, HCMV gN, HCMV gH, HCMV gL, HCMV gO, HCMV UL131a, HCMV UL130, HCMV UL128, HCMV UL83, Herpes Simplex virus type 1 (HSV1) gB, HSV1 gH, HSV1 gL, HSV1 gC, HSV1 gD, Herpes Simplex virus type 2 (HSV2) gB, gH, gL, gC, gD, Varicella Zoster virus (VZV) gB, VZV gH, VZV gL, VZV gM, VZV gN, VZV gE, VZV gI, VZV gC, VZV gK, cercopithecine herpesvirus 1 (CeHV1) gB, CeHVI-gH, CeHVI-gL, gC, and gD.

7. The nucleic acid molecule of claim 6 , wherein the second nucleic acid sequence encodes a HCMV protein selected from: gB, gM, gN, gH, gL, gO, UL131a, UL130, UL128, or UL83.

8. The nucleic acid molecule of claim 6 , wherein the second nucleic acid sequence encodes a HSV1 protein selected from gB, gH, gL, gC, or gD.

9. The nucleic acid molecule of claim 6 , wherein the second nucleic acid sequence encodes aHSV2 protein selected from gB, gH, gL, gC, or gD.

10. The nucleic acid molecule of claim 6 , wherein the second nucleic acid sequence encodes a VZV protein selected from gB, gH, gL, gM, gN, gE, gI, gC, or gK.

11. The nucleic acid molecule of claim 6 , wherein the second nucleic acid sequence encodes a CeHV1 protein selected from gB, gH, gL, gC, or gD.

12. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is a plasmid.

13. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is an expression vector, and the nucleic acid sequences encoding said one more proteins are operably linked to regulatory elements within said expression vector.

14. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is incorporated into a viral particle.

15. A composition comprising one or more nucleic acid molecules of claim 1 .

16. A method of inducing an immune response against a HCMV antigen in a subject comprising administering an effective amount of a nucleic acid molecule of claim 1 to a subject.

17. A HCMV protein encoded by a nucleic acid of claim 1 .

18. The protein of claim 17 , selected from the group consisting of:
a protein comprising SEQ ID NO:2;
a protein comprising SEQ ID NO:4;
a protein comprising SEQ ID NO:6;
a protein comprising SEQ ID NO:8;
a protein comprising SEQ ID NO:10;
a protein comprising SEQ ID NO:12;
a protein comprising SEQ ID NO:14;
a protein comprising SEQ ID NO:16;
a protein comprising SEQ ID NO:18; and
a protein comprising a protein comprising SEQ ID NO:20.

Assignees

• Weiner David B
• Shedlock Devon J
• Univ Pennsylvania

Inventors

• Weiner David B
• Shedlock Devon J

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/22

  for herpes viruses · CPC title

• C07K14/005 Primary

  from viruses · CPC title

• A61K39/25

  Varicella-zoster virus · CPC title

• A61K39/12

  Viral antigens · CPC title